Klin Farmakol Farm. 2015;29(3):108-112

The biologically active phospholipids isolated from egg yolk increasing cytotoxic effect of temozolomide

Jozef Hatok, Eva Blahovcová, Henrieta Škovierová, Radovan Murín

Univerzita Komenského v Bratislave, Jesseniova lekárska fakulta v Martine, Ústav lekárskej biochémie, Martin

on human glioblastoma cells

Extracts of biologically active phospholipids (BAP) may exert a positive effect on inhibition of tumor growth and may be used as additive

compounds to supplement palliative tumor treatment. The exact mechanisms by which BAP affect the cancer cells are still unknown.

Among brain tumors, glioblastoma multiforme (GBM) is considered the most aggressive and the most common primary brain tumor in

adults. The treatment of GBM includes surgery, radiotherapy and chemotherapy with an alkylating agent temozolomide (TMZ). With the

aim to study the survival of human glioblastoma cells, in media supplemented with BAP alone or in combination with TMZ, we used the

cell line T98G as a study model. The effect of BAP on glioblastoma cell survival was assessed by an methyl-thiazol tetrazolium (MTT) assay

and also microscopically. Cells were incubated in medium enriched with BAP of different final 1-O-octadecyl-2-oleoyl-sn-glycero-3-phospho-(

N-palmitoyl)ethanolamine (PNAE) concentrations in range 0,05 – 0,3 % (aBAP). Our results show that aBAP negatively affected the

cell survival, depending on their concentration in culture medium. Pre-culturing of the cells with aBAP for 24 hours before the incubation

with TMZ had potentiated the cytotoxic effect of TMZ on GBM cells. The results indicate that BAP with PNAE are capable to either inhibit

growth or induce the death of human glioblastoma cells in vitro. In conclusion, the capability of aBAP to potentiate the cytotoxic effect

of temozolomide indicates that further testing of aBAP as an adjunct agent to treat GBM, may be of great clinical significance.

Keywords: glioblastoma multiforme, chemoresistance, biologically active phospholipids, temozolomide

Published: December 1, 2015  Show citation